Grants and Contributions:
Title:
COVID-19 Rapid Response: Identifying & developing next-generation COVID-19 therapeutics
Agreement Number:
1002444
Agreement Value:
$6,325,000.00
Agreement Date:
Nov 1, 2022 - Mar 31, 2024
Description:
Identify and develop antibody therapeutics for response and preparedness against COVID-19, and expand capacity for rapid development and delivery of antibody therapeutics.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5Y 0A1
Reference Number:
172-2022-2023-Q4-1002444
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
838509446
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 375,000 dollars.
Amendment Date
Mar 27, 2024
Recipient's Operating Name:
AbCellera
Recipient's Legal Name:
AbCellera Biologics Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: